Efficacy and Safety of Filgotinib for the Treatment of Perianal Fistulising Crohn's Disease [DIVERGENCE 2]: A Phase 2, Randomised, Placebo-controlled Trial.

Background And Aims: There is an unmet need in the treatment of perianal fistulising Crohn's disease [PFCD]. This study evaluated the efficacy and safety of the Janus kinase 1 preferential inhibitor, filgotinib, for the treatment of PFCD.

Methods: This phase 2, double-blind, multicentre trial enrolled adults with PFCD and prior treatment failure.

Validation of the Thai Version of the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale.

Objective: This study aims to validate the Thai translation of the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS).

Methods: The English version was translated into Thai and then back-translated into English. The translated version underwent 2 rounds of cognitive pretesting to assess the ease of comprehension, ease of use and comfort with the scale.

Dynamic prediction using joint models of longitudinal and recurrent event data: A Bayesian perspective.

In cardiovascular disease (CVD) studies, the events of interest may be recurrent (multiple occurrences from the same individual). During the study follow-up, longitudinal measurements are often available and these measurements are highly predictive of event recurrences. It is of great clinical interest to make personalized prediction of the next occurrence of recurrent events using the available clinical information, because it enables clinicians to make more informed and personalized decisions and recommendations.

Prognostic Modeling of Parkinson's Disease Progression Using Early Longitudinal Patterns of Change.

Background: Predicting Parkinson's disease (PD) progression may enable better adaptive and targeted treatment planning.

Objective: Develop a prognostic model using multiple, easily acquired longitudinal measures to predict temporal clinical progression from Hoehn and Yahr (H&Y) stage 1 or 2 to stage 3 in early PD.

Methods: Predictive longitudinal measures of PD progression were identified by the joint modeling method.

Validation of the Polish version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS).

Background: In 2008, the Movement Disorders Society (MDS) published a new Unified Parkinson's Disease Rating Scale (MDS-UPDRS) as the official benchmark scale for Parkinson's Disease (PD). We have translated and validated the Polish version of the MDS-UPDRS, explored its dimensionality, and compared it to the original English one.

Methods: The MDS-UPDRS was translated into Polish by a team of Polish investigators led by JS and GO.

Validation of the Hebrew Version of the Unified Dyskinesia Rating Scale.

Background: The Unified Dyskinesia Rating Scale (UDysRS) is a well-established tool for producing comprehensive assessments of severity and disability associated with dyskinesia in patients with Parkinson's disease (PD). The scale was originally developed in English, and a broad international effort has been undertaken to develop and validate versions in additional languages. Our aim was to validate the Hebrew version of the UDysRS.

Successful use of the Unified Dyskinesia Rating Scale regardless of PD- or dyskinesia-duration.

Objective: We assessed differential item functioning (DIF) in the Unified Dyskinesia Rating Scale (UDysRS) to evaluate bias risk from the duration of Parkinson's Disease (PD) and duration of dyskinesia.

Background: Assessing DIF is a core validation step for rating scales. If DIF is present for an item, interpretation must consider influences from the tested covariates.

Missing Data in the Unified Dysksinesia Rating Scale (UDysRS).

Objective: Identify the number of allowable missing values still permitting valid surrogate score calculation for the Unified Dyskinesia Rating Scale (UDysRS).

Background: Missing data frequently occur in Parkinson's disease rating scales, and they compromise data validity, risking data exclusion from final analyses.

Methods: Accessing the International Parkinson and Movement Disorder Society-sponsored UDysRS translation databases (3313 complete scores).

Predictors of weight loss in early treated Parkinson's disease from the NET-PD LS-1 cohort.

Weight loss is a common symptom of Parkinson's disease and is associated with impaired quality of life. Predictors of weight loss have not been studied in large clinical cohorts. We previously observed an association between change in body mass index and change in Unified Parkinson's Disease Rating Scale (UPDRS) motor and total scores.

Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1.

Background: Monoamine oxidase type B (MAO-B) inhibitors exhibit neuroprotective effects in preclinical models of PD but clinical trials have failed to convincingly demonstrate disease modifying benefits in PD patients.

Objective: To perform a secondary analysis of NET-PD LS1 to determine if longer duration of MAO-B inhibitor exposure was associated with less clinical decline.

Methods: The primary outcome measure was the Global Outcome (GO), comprised of 5 measures: change from baseline in the Schwab and England (ADL) scale, the 39-item Parkinson's Disease Questionnaire (PDQ-39), the UPDRS Ambulatory Capacity Scale, the Symbol Digit Modalities Test, and the most recent Modified Rankin Scale.